Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04824716
Other study ID # IPOST-01, v2.0, Nov 22, 2012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2013
Est. completion date October 15, 2018

Study information

Verified date April 2021
Source Pharmahungary Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study was to investigate the efficacy of ischemic postconditioning in acute myocardial infarction patients. The safety of patients enrolled in the study was ensured during the entire study. Over 18 years old men and women were enrolled in the study who arrived to 2 of the most acknowledged Hungarian cardiac centres due to acute myocardial infarction and fulfilled all inclusion and exclusion criteria as per protocol. Patients in the order of their arrival were assigned either to control or post conditioned groups by turns. Medical treatment of the control group was done according to standard Percutaneous Coronary Intervention (PCI) guidelines, i.e. there was no further intervention after artery opening for 8 minutes, then stenting was performed. In the post conditioned group, after reperfusion has been confirmed, the coronary artery was occluded by inflation of the stent balloon 4 times (for 1-1 minute) followed by 1-1-minute reperfusion repeatedly to induce ischemic postconditioning. Postconditioning procedure was followed by stenting as in the control group. All other interventions and treatments in both patient groups were identical according to guidelines.


Description:

Over 18 years old men and women were enrolled in the study who arrived to 2 of the most acknowledged Hungarian cardiac centres due to acute myocardial infarction and fulfilled all inclusion and exclusion criteria as per protocol. Patients in the order of their arrival were assigned either to control or post conditioned groups by turns. After closing patient enrolment, further subgrouping will be performed in case sufficient group size has been achieved as follows: (1) normal, control, (2) normal, post conditioned, (3) hypercholesterolemic, not treated with statins, control, (4) hypercholesterolemic, not treated with statins, post conditioned, (5) statin treated, control, (6) statin treated, post conditioned. Characterisation of postconditioning is performed by the following parameters: 1. Blood tests 5 minutes before as well as 8, 60 minutes, 24 hours, and 3 months after PCI to measure nitrotyrosine, a biomarker of peroxynitrite formation (nitrosative stress) by ELISA; B-type natriuretic peptide, a biomarker of heart failure by ELISA; matrix metalloproteinase activities (MMP-2 and MMP-9) putative biomarkers of cardiac remodelling by zymography; microRNA expression pattern by sequencing and its validation by quantitative real-time polymerase chain reaction (PCR). 2. Routine laboratory tests 6, 12 and 48 hours after PCI including creatine kinase (CKMB) and cardiac troponin T (cTnT). 3. ECG immediately after recanalization and intervention after 60 and 90 minutes, then 12, 24, 36 and 48 hours later 12-lead ECG is registered. 4. Echocardiography: 48 hours after intervention, standard view to judge left ventricle segments movement disorders 5. Angiography: Blush, Syntax score, and ischemic risk zone (area at risk, AAR) are determined 6. cardiac late enhancement magnetic resonance (MR) imaging to determine infarct size At 3-month follow-up visit the following parameters were measured: echocardiography for restitution assessment, cardiac late enhancement MR imaging to determine infarct size and cardiac function, blood sampling for above mentioned biochemical laboratory tests


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 15, 2018
Est. primary completion date October 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Subject must be >18 years of age 2. Myocardial infarction with elevated ST 3. Chest pain onset less than 12 hours before PCI 4. concordant ST elevation (>0,1 mV) in at least 2 ECG leads 5. Occluded main proximal or middle main coronary ('Thrombolysis In Myocardial Infarction' flow grade: 0) diagnosed with coronarography 6. Coronary opened by PCI (TIMI 2 flow grade) 7. Awake, conscious, co-operating patient, who is able to retain his breath for 10 sec 8. Signed Patient Information Leaflet and Patient Informed Consent Form Exclusion Criteria: 1. Cardiogenic shock 2. Previous myocardial infarction in the area of the occluded coronary artery 3. Occluded coronary with visible collateral branches 4. Lack of co-operation 5. Current left or right bundle branch block (LBBB) 6. Malignant ventricle arrhythmia or atrial fibrillation 7. Killip class > 2 8. Known renal failure

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Postconditioning
The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
Device:
Percutaneous coronary intervention
Percutaneous coronary intervention as per European Society of Cardiology guidelines.

Locations

Country Name City State
Hungary Heart and Vascular Center, Semmelweis University Budapest
Hungary Department of Invasive Cardiology of Cardiology Center, Faculty of Medicine, University of Szeged Szeged
Hungary Pharmahungary Group Szeged

Sponsors (3)

Lead Sponsor Collaborator
Peter Ferdinandy Semmelweis University Heart and Vascular Center, Szeged University

Country where clinical trial is conducted

Hungary, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac magnetic resonance imaging Left and right ventricular function, myocardial scar, transmurality, diffusion spectrum imaging (DSI) measurement and evaluation 3 months after acute myocardial infarction
Secondary Echocardiography measurement of Cardiac Ejection Fraction Measurement of Cardiac Ejection Fraction using Teicholz and Simpson methods on both study arms. 48 hours and 3 months after acute myocardial infarction
Secondary Echocardiography measurement of cardiac left ventricular segments for wall motion abnormalities Calculation of cardiac wall motion score index on both study arms. 48 hours and 3 months after acute myocardial infarction
Secondary Laboratory measurement of blood Nitrotyrosine levels. Laboratory measurement of Nitrotyrosine levels in blood samples with ELISA on both study arms. 5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Secondary Laboratory measurement of blood MMP activity. Laboratory measurement of MMP activity in blood samples with zymography on both study arms. 5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Secondary Laboratory characterization of microRNA patterns with microRNA array Laboratory characterization of microRNA expression pattern in blood samples with with microRNA array on both study arms. 5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Secondary Validation of selected microRNA with quantitative real-time PCR Out of the differentially expressed microRNAs identified in Outcome 6, up to 10 different miRNAs will be selected for further validation of their specific expression change (expressed by fold-change) by quantitative real-time PCR in up to 10 randomly selected patients on both study arms, respectively. 5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Secondary Electrocardiography ST segment post-procedure evaluation Distortion in ST segment amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms. Post-procedure 60, 90 minutes, and 12, 24, 48 hours.
Secondary Electrocardiography T wave post-procedure evaluation Distortion in T wave amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms. Post-procedure 60, 90 minutes, and 12, 24, 48 hours.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05244707 - The Effects of a Mediterranean Style Diet in Heart Disease Patients Running a Cardiac Rehabilitation Program N/A
Not yet recruiting NCT03148834 - Dextran Use for Primary Angioplasty Protection in Acute Myocardial Infarction N/A
Enrolling by invitation NCT05800951 - Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
Recruiting NCT05431296 - Glucose Control Using Continuous Glucose Monitoring in People With Type 2 Diabetes Who Have Had Acute Myocardial Infarct N/A
Active, not recruiting NCT03744000 - Deferred Stenting in Patients With Anterior Wall STEMI N/A